Abstract
High-density lipoproteins (HDLs) have presented an attractive target for development of new therapies for cardiovascular prevention on the basis of epidemiology and preclinical studies demonstrating their protective properties. Development of HDL mimetics provides an opportunity to administer functional HDL. However, clinical trials have produced variable results, with no evidence to date that they reduce cardiovascular events. This article reviews development programs of HDL mimetics.
| Language | English |
|---|---|
| Pages | 311-315 |
| Number of pages | 5 |
| Journal | Cardiology Clinics |
| Volume | 36 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 May 2018 |
Keywords
- Atherosclerosis
- Cardiovascular risk
- High-density lipoproteins
- Lipids
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
}
High-Density Lipoprotein Infusions. / Takata, Kohei; Di Bartolo, Belinda A.; Nicholls, Stephen J.
In: Cardiology Clinics, Vol. 36, No. 2, 01.05.2018, p. 311-315.Research output: Contribution to journal › Review article
TY - JOUR
T1 - High-Density Lipoprotein Infusions
AU - Takata, Kohei
AU - Di Bartolo, Belinda A.
AU - Nicholls, Stephen J.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - High-density lipoproteins (HDLs) have presented an attractive target for development of new therapies for cardiovascular prevention on the basis of epidemiology and preclinical studies demonstrating their protective properties. Development of HDL mimetics provides an opportunity to administer functional HDL. However, clinical trials have produced variable results, with no evidence to date that they reduce cardiovascular events. This article reviews development programs of HDL mimetics.
AB - High-density lipoproteins (HDLs) have presented an attractive target for development of new therapies for cardiovascular prevention on the basis of epidemiology and preclinical studies demonstrating their protective properties. Development of HDL mimetics provides an opportunity to administer functional HDL. However, clinical trials have produced variable results, with no evidence to date that they reduce cardiovascular events. This article reviews development programs of HDL mimetics.
KW - Atherosclerosis
KW - Cardiovascular risk
KW - High-density lipoproteins
KW - Lipids
UR - http://www.scopus.com/inward/record.url?scp=85042175643&partnerID=8YFLogxK
U2 - 10.1016/j.ccl.2017.12.012
DO - 10.1016/j.ccl.2017.12.012
M3 - Review article
VL - 36
SP - 311
EP - 315
JO - Cardiology Clinics
T2 - Cardiology Clinics
JF - Cardiology Clinics
SN - 0733-8651
IS - 2
ER -